Michael Scheurer, PhD, MPH, FACE (left), and Mylin Torres, MD, are the CPC Program's new co-leader and clinical translational liaison.
Winship Cancer Institute of Emory University has announced new leadership appointments for the Cancer Prevention and Control (CPC) Research Program to further support the program’s growth and commitment to translational research.
Molecular epidemiologist Michael Scheurer, PhD, MPH, FACE, professor of pediatrics at Emory University School of Medicine, has been named co-leader of the CPC Program. Scheurer will serve alongside co-leader Ilana Graetz, PhD, to oversee the program’s continued growth and efforts to enhance the scientific impact of Winship’s research. He will play a key role in strategic development, membership activities, pilot funding, research opportunities and other initiatives aligned with Winship’s mission and strategic plan and in support of the CPC Program’s goals.
After seven years of dedicated service as co-leader of the CPC Program, Mylin Torres, MD, will move into a new role as the program’s clinical translational liaison. A physician and professor of radiation oncology at Emory University School of Medicine, Torres will work closely with CPC Program co-leaders to provide clinical insight and guidance for the continued growth of the program. She will help identify clinical partners for our investigators, promote interactions between clinical investigators and research faculty and identify sources of biospecimens to support cancer research relevant to the communities Winship serves.
“We are grateful for Dr. Torres's outstanding contributions and delighted to welcome Dr. Scheurer to the leadership team,” says Suresh S. Ramalingam, MD, FACP, FASCO, executive director of Winship. “Together, their new appointments reflect Winship’s strategic commitment to strengthening the connection between scientific discovery, clinical care and population-level impact with the goal of improving outcomes for patients and communities impacted by cancer.”